

# Sleep Disturbances as a Manifestation of Neurodevelopmental Disorders

---

## Abstract:

Sleep disturbances are complex elements of many neurodevelopmental disorders, such as autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), intellectual and developmental disabilities, and insomnia. Sleep disturbances are caused by a variety of factors, resulting in short-term and long-term consequences that can affect self-care, daily functions, and well-being. Sleep disturbances can compromise not only the general health of individuals but also on the health of caregivers and support systems. There is a need to understand the interaction between neurodevelopmental disorders and sleep disturbances to identify patterns of sleep fragmentations contributed to neurobiological and neurodevelopmental conditions, determine appropriate treatment, improve the quality of life for individuals with neurological comorbidities.

Comment [HE1]: Add space

Comment [HE2]: Add space

Comment [HE3]: the

Comment [HE4]:

Comment [HE5]: There is need to improve the abstract by stating the problem, method of study eg desk top or library research, the selection of literature reviewed, and the findings in brief.

Comment [HE6]: Include Key words

## 1) Introduction:

Sleep disturbance is a typical area of focus reported by parents to their children's pediatrician. Approximately 25 % of typically developing preschool-aged children suffer sleep conditions due to sleep start delays and nocturnal awakenings [1, 2]. Sleep problems in children with neurodevelopmental disorders (NDD) are significantly more widespread. In NDD, the prevalence of sleep disturbances has been reported to be as high as 86 % [3]. Sleep problems are included in the diagnostic criteria for many NDDs, encompassing several medical and psychiatric conditions. The prevalence of sleep disturbances is higher in growing children, and unlike typically developing persons, sleep abnormalities in children with NDD commonly linger into adolescence and adulthood [4].

The etiology of sleep disruptions in neurodevelopmental disorders (NDD) is characterized by the involvement of many factors. Sleep disturbances can arise from various factors, including medical and neurological disorders such as gastroesophageal reflux and epileptic seizures, behavioral issues like inadequate sleep hygiene and environmental factors, the use of medications, psychiatric disorders like depression, bipolar disorder, and post-traumatic stress disorder, and specific sleep disorders such as obstructive sleep apnea and restless legs syndrome. Diverse interventions may be necessary to address sleep and behavioral difficulties in children with distinct developmental impairments. Some individuals may require additional melatonin supplementation for the management of insomnia or circadian rhythm abnormalities, whereas others may necessitate interventions targeting obstructive sleep apnea. Sleep disturbances commonly observed in neurodevelopmental disorders (NDD) may be associated with two primary issues: insomnia, which encompasses difficulties with both initiating and maintaining sleep, and hypersomnia [5-9].

## **1.1. The Complex Relationship Between Sleep and Neurodevelopmental Disorders**

Sleep disturbances in individuals with neurodevelopmental disorders are often multifaceted. They can be attributed to various factors, including genetic predispositions, altered circadian rhythms, sensory sensitivities, anxiety, and behavioral difficulties. These factors may interact and compound the sleep issues faced by these individuals[10, 11].

### **1.1.1. Autism Spectrum Disorder :**

Children with Autism Spectrum Disorder (ASD) frequently experience sleep disturbances, with problems of difficulty falling asleep, frequent awakenings during the night, and early morning waking. These issues can exacerbate the core symptoms of ASD, such as impaired social interaction, communication difficulties, and repetitive behaviors. Although the exact cause of sleep disturbances in ASD is not fully understood, ASD is thought to be related to atypical neural functioning and sensory sensitivities. Sensory overstimulation or hypersensitivity to sensory stimuli can make falling and staying asleep a significant challenge for individuals with ASD[12].

### **1.1.2. Attention-DeficitHyperactivity Disorder:**

Sleep disturbances are also common in individuals with Attention-deficit hyperactivity disorder (ADHD). Individuals may struggle with hyperactivity, impulsivity, and inattention during the day, which can lead to bedtime resistance and difficulty falling and staying asleep at night. Moreover, individuals with ADHD might experience restless leg syndrome, periodic limb movement disorder, and other sleep-related conditions that further disrupt their sleep patterns[13, 14].

### 1.1.3. Intellectual Developmental Disabilities:

Individuals with intellectual developmental disabilities often have a higher prevalence of sleep disturbances. They may experience difficulties with self-soothing, communication, and understanding bedtime routines, making it challenging for caregivers to establish regular sleep patterns. These sleep issues can compound the challenges that individuals with intellectual disabilities already face in their daily lives[15-17].

## 2. Sleep Disorders In People With Intellectual Developmental Disability

Sleep disturbances are frequently observed among individuals with intellectual developmental disabilities, as evidenced by the prevalence rates of sleep difficulties in children ranging from 24% to 86% [18]. The prevalence of sleep disturbances among persons with intellectual developmental disabilities is reported to range from 8.5% to 34.1%, with a notable 9.2% suffering substantial sleep difficulties. A significant proportion of older adults with an intellectual developmental disability, specifically 72% out of a sample size of 551 individuals in a study, experienced sleep issues [18, 19].

The investigation of mental and physical health conditions and their corresponding therapy in individuals with intellectual developmental disabilities is an area that has received limited attention. Diagnostic and management procedures are frequently derived from research conducted on individuals who do not have intellectual developmental disability. Sleep disturbances in persons with intellectual impairments may have a consistent pattern. The limited data available on the etiology and consequences of sleep issues in individuals with intellectual developmental disorders highlight the need for further investigation and intervention in this area [20]. Gaining insight into the various sleep issues encountered by persons with intellectual

Comment [HE7]: Add space

impairments and comprehending the multitude of factors that impact their sleep can contribute to the evaluation and treatment of sleep difficulties in this population [21].

There exist multiple plausible rationales for the heightened prevalence of sleep disturbances among adults with intellectual developmental disabilities. .. A systematic review conducted on sleep disturbances in persons with intellectual impairments revealed significant correlations between sleep patterns and several characteristics such as challenging behavior, the use of psychotropic medication, mental health issues, and respiratory diseases [22].

### 3. Neurodevelopmental Conditions

Autism spectrum disorder (ASD) frequently co-occurs with intellectual developmental disabilities, presenting as a comorbidity. The prevalence of ASD in persons with moderate to profound intellectual disability can reach up to 39% [23]. Individuals with ASD frequently experience chronic sleep disturbances throughout their lifespan. A comparative analysis of circadian rhythms and sleep patterns in persons diagnosed with ASD and intellectual difficulties was compared to a control group of typically developing adults and identified a correlation [24]. The results of **study** revealed that adults diagnosed with ASD and intellectual developmental disabilities have an extended period of time before falling asleep, more frequent and longer awakenings during the night, and reduced effectiveness of sleep when compared to adults who do not have a neurodevelopmental disorders. The multifaceted origins of sleep difficulties in individuals with ASD [26], and several factors contribute to biological irregularities in the timing of melatonin release and disruptions in sleep patterns resulting from concurrent medical and mental illnesses [25].

Attention-deficit hyperactivity disorder (ADHD) is a complex condition that affects brain activity and functions. Individuals with intellectual disabilities have a greater incidence of ADHD compared to those without intellectual developmental disabilities, with reported rates reaching as high as 19.6%. Sleep disturbances are a prevalent concern that impacts those diagnosed with ADHD, with documented prevalence rates reaching as high as 50% among this population. Numerous hypotheses **exists** to elucidate the underlying causes of sleep disturbances in individuals with ADHD. A multifaceted association between sleep and ADHD suggests that disrupted sleep may be an inherent characteristic of ADHD, which is further influenced by the

Comment [HE8]: Results of the

Comment [HE9]:

Comment [HE10]: exist

impact of psychostimulant treatment [28]. Despite the established correlation, sleep difficulties associated with ADHD may be categorized as a challenging condition to understand " among persons who also have co-occurring intellectual developmental disability.

#### 4. Genetic Conditions

In recent times, there has been notable advancement in comprehending the fundamental genetic components contributing to the onset of intellectual impairments. The distinctive attributes of Down's syndrome encompass hypotonia, obesity, and craniofacial anomalies, all of which heighten the susceptibility to sleep-disordered breathing conditions, such as obstructive sleep apnea (OSA). Individuals diagnosed with cri du chat syndrome exhibit a heightened susceptibility to the development of OSA. Individuals diagnosed with Smith-Magenis syndrome exhibit an elevated susceptibility to circadian sleep-wake disorders, commonly characterized by an inverted sleep-wake cycle that is believed to arise from an abnormality in the melatonin system [26-29].

Comment [HE11]: delete

#### 5. Psychological And Environmental Factors

Sleep disruption frequently serves as a first indicator of declining mental well-being among individuals with mental illness, whereas inadequate sleep is a fundamental manifestation of numerous affective and psychotic disorders. The elevated occurrence of sleep problems among individuals with intellectual impairments can be comprehended within the framework of the heightened frequency of mental illnesses in this population, relative to individuals without intellectual developmental disabilities [30, 31].

The consideration of the environment's influence on the development of sleep disorders is a crucial aspect in determining the underlying causes of sleep issues in individuals with intellectual developmental disabilities. Sleep cycles of individuals in residential homes may be compromised due to nocturnal staff check-ins, which can lead to heightened levels of interactions and lights that disrupt the sleep patterns of residents[35]. Additional environmental factors that should be taken into account for individuals residing in supported living facilities encompass the potential presence of cohabitants experiencing sleep disturbances, which may result in disruptive

nocturnal noises. Furthermore, the limited availability of outdoor activities that facilitate exposure to natural light should be considered. **The Impact of Sleep Disturbances:**

**Comment [HE12]:** Move this to the next line in order for it to be a subheading

Sleep disturbances can have a profound impact on the daily lives of individuals with neurodevelopmental disorders. The consequences of poor sleep quality are far-reaching and may include[32-34]:

- **Cognitive Impairments:** Sleep disturbances can exacerbate cognitive impairments in individuals with neurodevelopmental disorders, affecting their learning and overall development.
- **Behavioral Problems:** Poor sleep can lead to increased irritability and challenging behaviors, which can further disrupt family dynamics.
- **Impaired Quality of Life:** For both individuals and their families, sleep disturbances can contribute to a decreased quality of life and increased stress.

## **6. Analysis of Phenotypes for Sleep Disorder**

Various sleep assessment approaches should be tailored to suit the individual needs of each child. Parent-reported questionnaires and sleep diaries are commonly utilized subjective tools in the examination of sleep problems. The key benefits associated with these approaches is the non-invasive nature that allows for the collection of data without causing harm or discomfort to the child as well as the cost-effectiveness of journaling sleep activities. The Children's Sleep Habits Questionnaire (CSHQ) is widely recognized as a prominent survey completed by parents whereby the questionnaire is designed to evaluate the sleep patterns of school-aged children through the collection of information provided by parents. Another technique that can be employed is Electroencephalography (EEG) that requires the attachment of two electrodes to a patient's scalp. The device offers a comprehensive record of the brain's EEG patterns throughout both sleep and periods of reduced physical strength. The polysomnogram (PSG) approach is widely recognized as the standard for objectively evaluating sleep, in contrast to a single-channel EEG. The assessment includes physiological indicators of both typical and atypical brain electrical patterns, the structure of sleep, the various stages of sleep, the overall quality of sleep, as well as eye movements and bodily movements exhibited during sleep. Actigraphy is a method that allows for the assessment of limb activity in a non-invasive manner that is achieved by

utilizing an accelerometer to detect and distinguish periods of sleep and alertness. The actigraphy technology facilitates the gathering of data over extended periods of time inside unstructured environments. The study investigated the reliability of actigraphy in conjunction with polysomnography (PSG) and found a robust correlation ( $>0.80$ ) between PSG and actigraphy measurements for sleep latency, duration, and efficiency [A citation is needed]. Videosomnography, akin to actigraphy, derives its advantages from its ability to provide objective documentation over an extended duration. Though the utilization of videosomnography in the field of child sleep research has various challenges [35-40], it has the capability to document atypical events such as parasomnias that occur during the nighttime [39-44].

**Comment [HE13]:** Add source reference

## 7. Addressing Sleep Disturbances In Neurodevelopmental Disorders:

Managing sleep disturbances in individuals with neurodevelopmental disorders can be complex and requires a tailored approach. Some strategies to consider include:

**Comment [HE14]:** Add reference to substantiate this

- **Behavioral Interventions:** Implementing consistent bedtime routines and positive reinforcement for good sleep behavior can be effective.
- **Medication:** In some cases, medication may be prescribed to manage specific sleep-related issues, such as insomnia or restless leg syndrome.
- **Sensory Accommodations:** For individuals with sensory sensitivities, creating a sleep environment that minimizes sensory triggers can be helpful.
- **Therapies:** Behavioral therapy and social stories can be used to help individuals with neurodevelopmental disorders understand and follow sleep routines.
- **Collaboration:** Working with healthcare professionals, including pediatricians, sleep specialists, and therapists, can provide valuable insights and strategies for managing sleep disturbances.

Early and frequent screenings for sleep impairment and its related conditions are recommended.

7.1. **Non-Pharmacological Management:** The management of sleep problems in children and adolescents diagnosed with Autism Spectrum Disorder (ASD) necessitates a comprehensive approach that addresses both environmental and behavioral factors. Parents should establish consistent sleep habits and provide a conducive bedroom

environment for their children. The implementation of environmental and behavioral interventions can enhance sleep quality, though may pose some challenges in their practical application for some children with difficulty adhering to sleep regimens. The Sleep Committee of the Autism Treatment Network devised a specialized behavioral modification tool known as the sleep tool kit (STK) to address sleeplessness in children and adolescents. The STK framework proposes three strategies: the implementation of visual schedules to promote appropriate evening behaviors, the incorporation of a supplementary relaxation module to decrease levels of arousal, and the gradual fading of nighttime routines to facilitate sleep onset while experiencing fatigue. Various adjunctive interventions including as breathing methods, muscular relaxation exercises, yoga, massage, mindfulness training, and warm baths have been found to be beneficial in assisting patients in managing their levels of arousal and anxiety. Considering the developmental attributes of children with ASD, research indicates that implementing positive routines, employing unmodified and progressive extinction techniques, and utilizing overnight fading strategies are particularly advantageous for children aged 5 and below. For older children and adolescents, cognitive-behavioral therapy (CBT) has been found to yield greater benefits [41-45].

- 7.2. **Pharmacological Management:** Medical intervention is deemed necessary in cases where children do not exhibit positive responses to behavioral therapy.
- 7.3. **Role of Melatonin:** Individuals with Autism Spectrum Disorder may experience sleep issues and changes in their circadian rhythm due to a reduced level of sociability [50-52]. Certainly, zeitgebers, which are sometimes referred to as timeivers, play a crucial role in the entrainment and synchronization of the circadian clock. Examples of these zeitgebers are the natural light-dark cycle, music, and social cues. Individuals diagnosed with ASD may experience difficulties in seeing or interpreting social cues, which can potentially hinder the functionality of mechanisms responsible for regulating sleep and wakefulness. In contrast, individuals diagnosed with ASD may encounter challenges in effectively coordinating their internal and external environments, resulting in subsequent disruptions to rhythm and temporal processes. These disruptions can have wide-ranging implications, encompassing areas such as social engagement and circadian rhythms. Individuals with ASD may exhibit disruptions in their circadian rhythms as a result of their inability to

Comment [HE15]: Space out

synchronize their internal biological clock with external environmental and social cues [46-51]. A range of over-the-counter formulations of melatonin is available, with doses ranging from 1 to 10 mg with a commonly recommended dosage of 1–3 mg approximately 30–60 minutes prior to the intended time of sleep initiation, though the dosage may vary for every individual. A recommended administration of a smaller dosage (0.5-1 mg) at an earlier time (3-4 hours before bedtime) if a circadian rhythm disorder is identified [56-59]. The efficacy of a dose is not influenced by an individual's age or weight. Melatonin is a hormone produced by the pineal gland that regulates the circadian rhythm of the body. The efficacy of melatonin in lowering sleep onset latency is evident, but, its usefulness in mitigating nocturnal awakenings and other disturbances in sleep patterns exhibits variability. In a study with a sample of 24 children diagnosed with ASD between the age range of 1 to 3 years revealed that the participants demonstrated a reduction in the time it took them to fall asleep, as measured by actigraphy, when administered either a 1 mg or 3 mg dosage. The intervention demonstrated significant enhancements in both the sleep patterns of the children as well as their behavior and the levels of stress experienced by their parents [52-55].

**Comment [HE16]:** Add references

- 7.4. **Antipsychotic Medication:** There is limited tolerability and efficacy data available for the use of antipsychotic medication class in the treatment of insomnia among pediatric patients. Several studies examining the impact on sleep architecture have reported that ziprasidone, olanzapine, and risperidone have the effect of increasing slow-wave sleep. Notably, both ziprasidone and risperidone have been found to decrease REM sleep. Risperidone and olanzapine are two atypical antipsychotic medications that have been suggested as potential treatments for sleep disturbances in pediatric patients. These drugs are utilized off-label for the management of insomnia, and it is not recommended to routinely prescribe them for this purpose, especially as a primary pharmacotherapeutic intervention. The Canadian Academy of Child and Adolescent Psychiatry issued guidance recommending against the initial use of these medications for the treatment of insomnia in individuals across several age groups, including children, adults, and the elderly. Similarly, several nations have also made efforts to restrict the quantity of prescriptions permitted under government-subsidized programs [56-61].

- 7.5. **Antidepressant:** The available information regarding the utilization and efficacy of sedative antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), in addressing sleep disorders among children with ASD is limited. The potential efficacy of these drugs may be observed in cases where insomnia is accompanied by concurrent psychiatric conditions. The administration of sedative antidepressants such as trazodone and mirtazapine may be advantageous for children who have comorbid depression. These pharmacological agents exert their therapeutic effects on sleep by modulating the activity of neurotransmitters associated with wakefulness, such as acetylcholine, histamine, noradrenaline, and serotonin. A notable consequence of these drugs is their tendency to diminish REM sleep and extend periods of daytime sleepiness. Trazodone is commonly selected and utilized in the field of psychiatry. The efficacy of this intervention has predominantly been demonstrated in individuals diagnosed with psychiatric disorders. The administration of Trazodone is associated with a discernible residual impact in the morning, which can be attributed to its antagonistic activity on the 5-HT<sub>2A/C</sub> receptors and its potent sedating properties as an antidepressant. There is an association between fluoxetine and the occurrence of sleeplessness. In comparison to the dosages used for the treatment of mood disorders, dosages administered for the management of insomnia are generally of a lesser magnitude [62-67].
- 7.6. **Alpha-Adrenergic Agonist:** The two main alpha agonists that are widely used off-label to treat autism-related sleep disturbances are clonidine and guanfacine. The administration of clonidine within a dosage range of 0.05-0.225 mg per day yielded reductions in sleep onset and maintenance difficulties experienced by children and adolescents (aged 4-16 years) diagnosed with autism and neurodevelopmental disorders. This treatment approach shown favorable tolerability and minimal occurrence of adverse effects. Some potential adverse effects of clonidine include hypotension, irritability, bradycardia, dry mouth, and suppression of REM sleep. Abrupt discontinuation of clonidine may lead to rebound hypertension and rebound REM sleep [68-70].
- 7.7. **Sedative and Hypnotics Drugs:** Benzodiazepines (BZDs), which are classified as hypnotics and sedatives, are commonly prescribed to adult patients experiencing insomnia. As a result of the adverse effects associated with benzodiazepines, such as

somnolence, cephalalgia, cognitive dysfunction, vertigo, and the development of tolerance and withdrawal symptoms, these medications are less usually prescribed for pediatric patients. The use of clonazepam, an intermediate-acting benzodiazepine (BZD), has been observed to yield positive outcomes in children diagnosed with developmental impairments who exhibit symptoms of partial arousals, parasomnias, periodic limb movement disorder, and nocturnal biting [71-73].

- 7.8. **Other Medications:** Several medications which are used in the treatment of the Alzheimer's disease are also found to be effective in the management of ASD symptoms. Drugs such as donepezil and rivastigmine are cholinesterase inhibitors that increase the acetylcholine by preventing its destruction. ASD is associated with anomalies in the cholinergic system that was discovered in post-mortem brain samples from people with ASD [1, 74-76].

## Conclusion:

Sleep disturbances are a common symptom of neurodevelopmental disorders, and these disturbances can have a significant impact on the lives of the individuals who experience them as well as the lives of their families. Recognizing the complexity of the relationship between sleep and a variety of disorders is vital for the development of successful treatments, as well as for boosting the general well-being and quality of life of individuals. Sleep plays a critical role in the body's natural healing process, hormonal balance, functions, and biological components. Neurodevelopmental disorders are complex conditions, it is absolutely necessary to implement a comprehensive and individualized approach to the management of sleep disturbances to meet the requirements that are unique to each individual with and without intellectual developmental disabilities. Early detection of neurodevelopmental disorders may yield promising treatment approaches to improve sleep quality and duration.

## Reference:

1. Chamseddin, B.H., R.F. Johnson, and R.B. Mitchell, *Obstructive sleep apnea in children with Down syndrome: demographic, clinical, and polysomnographic features*. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery*, 2019. **160**.

**Comment [HE17]:** Be consistent  
Neurodevelopmental disorder

**Comment [HE18]:**

The structure is fairly done but could be improved to include the key words, guiding research questions/research objectives, the literature review (if possible add a supporting theory) and the methodology section.

2. Chaste, P., N. Clement, and O. Mercati, *Identification of pathway-biased and deleterious melatonin receptor mutants in autism spectrum disorders and in the general population*. PLoS one., 2010. **5**.
3. Clayton-Smith, J., *Clinical research on Angelman syndrome in the United Kingdom: observations on 82 affected individuals*. American journal of medical genetics., 1993. **46**.
4. Cohen, M., J. Hamilton, and I. Narang, *Clinically important age-related differences in sleep related disordered breathing in infants and children with Prader-Willi Syndrome*. PLoS one., 2014. **9**.
5. Cohen, S., et al., *The relationship between sleep and behavior in autism spectrum disorder (ASD): a review*. Journal of neurodevelopmental disorders., 2014. **6**.
6. Cohen-Zion, M. and S. Ancoli-Israel, *Sleep in children with attention-deficit hyperactivity disorder (ADHD): a review of naturalistic and stimulant intervention studies*. Sleep medicine reviews., 2004. **8**.
7. Conant, K.D., R.L. Thibert, and E.A. Thiele, *Epilepsy and the sleep-wake patterns found in Angelman syndrome*. Epilepsia., 2009. **50**.
8. Cotton, S. and A. Richdale, *Brief report: parental descriptions of sleep problems in children with autism, Down syndrome, and Prader-Willi syndrome*. Research in developmental disabilities., 2006. **27**.
9. Craig, M.E., C.T. Cowell, and P. Larsson, *Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database)*. Clinical endocrinology., 2006. **65**.
10. Cua, C.L., et al., *Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates*. Pediatric cardiology, 2007. **28**.
11. Dan, B., *Angelman syndrome*. 2008.
12. Duis, J., et al., *A multidisciplinary approach to the clinical management of Prader-Willi syndrome*. Molecular genetics & genomic medicine., 2019. **7**.
13. Farhood, Z., J.W. Isley, and A.A. Ong, *Adenotonsillectomy outcomes in patients with Down syndrome and obstructive sleep apnea*. The Laryngoscope, 2017. **127**.
14. Friedman, M., O. Jacobowitz, and M.S. Hwang, *Targeted hypoglossal nerve stimulation for the treatment of obstructive sleep apnea: six-month results*. The Laryngoscope, 2016. **126**.
15. Giménez, S., L. Videla, and S. Romero, *Prevalence of sleep disorders in adults with Down syndrome: a comparative study of self-reported, actigraphic, and polysomnographic findings*. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2018. **14**.
16. Goffinski, A., M.A. Stanley, and N. Shepherd, *Obstructive sleep apnea in young infants with Down syndrome evaluated in a Down syndrome specialty clinic*. American journal of medical genetics Part A, 2015. **167a**.
17. Goldman, S.E., K.W. Adkins, and M.W. Calcutt, *Melatonin in children with autism spectrum disorders: endogenous and pharmacokinetic profiles in relation to sleep*. Journal of autism and developmental disorders., 2014. **44**.
18. Brugha, T.S., et al., *Epidemiology of autism in adults across age groups and ability levels*. The British Journal of Psychiatry, 2016. **209**(6): p. 498-503.
19. Baker, E.K. and A.L. Richdale, *Sleep patterns in adults with a diagnosis of high-functioning autism spectrum disorder*. Sleep, 2015. **38**(11): p. 1765-1774.
20. Hvolby, A., *Associations of sleep disturbance with ADHD: implications for treatment*. ADHD Attention Deficit and Hyperactivity Disorders, 2015. **7**(1): p. 1-18.
21. Cohen, S., et al., *The relationship between sleep and behavior in autism spectrum disorder (ASD): a review*. Journal of neurodevelopmental disorders, 2014. **6**(1): p. 1-10.

22. La Malfa, G., et al., *Detecting attention-deficit/hyperactivity disorder (ADHD) in adults with intellectual disability: The use of Conners' Adult ADHD Rating Scales (CAARS)*. Research in developmental disabilities, 2008. **29**(2): p. 158-164.
23. Korb, L., B. Perera, and K. Courtenay, *Challenging behaviour or untreated ADHD?* Advances in Mental Health and Intellectual Disabilities, 2019. **13**(3/4): p. 152-157.
24. Perera, B. and K. Courtenay, *ADHD and challenging behaviour in people with intellectual disability: should we screen for ADHD?* Psychiatria Danubina, 2017. **29**(suppl. 3): p. 562-564.
25. Didden, R. and J. Sigafoos, *A review of the nature and treatment of sleep disorders in individuals with developmental disabilities*. Res Dev Disabil, 2001. **22**(4): p. 255-72.
26. Ilyas, M., et al., *The genetics of intellectual disability: advancing technology and gene editing*. F1000Res, 2020. **9**.
27. Hill, E.A., *Obstructive sleep apnoea/hypopnoea syndrome in adults with Down syndrome*. Breathe (Sheff), 2016. **12**(4): p. e91-e96.
28. Maas, A.P., et al., *Exploration of differences in types of sleep disturbance and severity of sleep problems between individuals with Cri du Chat syndrome, Down's syndrome, and Jacobsen syndrome: A case control study*. Research in developmental disabilities, 2012. **33**(6): p. 1773-1779.
29. Elsea, S.H. and S. Girirajan, *Smith-Magenis syndrome*. Eur J Hum Genet, 2008. **16**(4): p. 412-21.
30. Selsick, H. and D. O'Regan, *Sleep disorders in psychiatry*. BJPsych Advances, 2018. **24**(4): p. 273-283.
31. Buckles, J., R. Luckasson, and E. Keefe, *A systematic review of the prevalence of psychiatric disorders in adults with intellectual disability, 2003–2010*. Journal of Mental Health Research in Intellectual Disabilities, 2013. **6**(3): p. 181-207.
32. Goldman, S.E., et al., *Sleep in children and adolescents with Angelman syndrome: association with parent sleep and stress*. Journal of intellectual disability research : JIDR., 2012. **56**.
33. Gombos, F., R. Bódizs, and I. Kovács, *Atypical sleep architecture and altered EEG spectra in Williams syndrome*. Journal of intellectual disability research : JIDR., 2011. **55**.
34. Graaf, G., F. Buckley, and B.G. Skotko, *Estimation of the number of people with Down syndrome in the United States*. Genetics in medicine : official journal of the American College of Medical Genetics., 2017. **19**.
35. Bhargava, S., *Diagnosis and management of common sleep problems in children*. Pediatrics in Review, 2011. **32**(3): p. 91-99.
36. Weber, F. and Y. Dan, *Circuit-based interrogation of sleep control*. Nature, 2016. **538**(7623): p. 51-59.
37. O'Donnell, S., C.M. Beaven, and M.W. Driller, *From pillow to podium: a review on understanding sleep for elite athletes*. Nature and science of sleep, 2018: p. 243-253.
38. Bélanger, M.-È., et al., *Validating actigraphy as a measure of sleep for preschool children*. Journal of Clinical Sleep Medicine, 2013. **9**(7): p. 701-706.
39. Honomichl, R.D., et al., *Secretin and sleep in children with autism*. Child Psychiatry and Human Development, 2002. **33**: p. 107-123.
40. Goldman, S.E., et al., *Parental sleep concerns in autism spectrum disorders: variations from childhood to adolescence*. J Autism Dev Disord, 2012. **42**(4): p. 531-8.
41. Hoffmire CA, Magyar CI, Connolly HV, Fernandez ID, Van Wijngaarden E. *High Prevalence of Sleep Disorders and Associated Comorbidities in a Community Sample of Children with Down Syndrome*. J Clin Sleep Med. 2014;10(4):411–9.
42. Donaldson ME, Chu CE, Cooke A. *The Prader-Willi syndrome*. Arch Dis Child. 1994;70(1):58–63.
43. Holm A, Cassidy B, Whitman Y, Butler C. *Prader-Willi syndrome : consensus diagnostic criteria*. Pediatrics. 1993;91(2):398–402.

44. Hoyt RW, Scarpa N, Wilmott RW, Cohen A, Schwartz E. Pulmonary function abnormalities in homozygous beta-thalassemia. *J Pediatr.* 1986;109(3):452–5.
45. Cohen M, Hamilton J, Narang I. Clinically important age-related differences in sleep related disordered breathing in infants and children with Prader-Willi syndrome. *PLoS ONE.* 2014;9(6):e101012.
46. Malow BA MS. Sleep and autism spectrum disorders. In: Tuchman R RI, editor. *Autism: a neurological disorders of early brain development.* Vol London: MacKeith Press; 2006. pp 188–201.
47. Bourgeron T. The possible interplay of synaptic and clock genes in autism spectrum disorders The possible interplay of synaptic and clock genes in autism spectrum disorders. 2007;LXXII (Freitag):645–654.
48. Veatch OJ, Goldman SE, Adkins KW, Malow BA. Melatonin in children with autism spectrum disorders : how does the evidence fit together. *J Nat Sci.* 2015;1(7):13–15. This review looks at how genetic variations in the melatonin pathway affects insomnia in ASD.
49. *Diagnostic and statistical manual of mental disorders.* 2013, Washington DC: American Psychiatric Association.
50. Accardo, J.A. and B.A. Malow, *Sleep, epilepsy, and autism.* *Epilepsy Behav,* 2014. **47.**
51. Ackermann, K. and J.H. Stehle, *Melatonin synthesis in the human pineal gland: advantages, implications, and difficulties.* *Chronobiology international.,* 2006. **23.**
52. Allen, K.D., et al., *Evaluation of a behavioral treatment package to reduce sleep problems in children with Angelman Syndrome.* *Research in developmental disabilities.,* 2013. **34.**
53. Allik, H., J.O. Larsson, and H. Smedje, *Sleep patterns of school-age children with Asperger syndrome or high-functioning autism.* *Journal of autism and developmental disorders.,* 2006. **36.**
54. Alsubie, H.S. and D. Rosen, *The evaluation and management of respiratory disease in children with Down syndrome (DS).* *Paediatric respiratory reviews.,* 2018. **26.**
55. Amaddeo, A., et al., *Polysomnographic findings in Rett syndrome.* *European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.,* 2019. **23.**
56. Amir, R.E., et al., *Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2.* *Nature genetics.,* 1999. **23.**
57. Andreou, G., et al., *Cognitive status in Down syndrome individuals with sleep disordered breathing deficits (SDB).* *Brain and cognition,* 2002. **50.**
58. Angriman, M., et al., *Sleep in children with neurodevelopmental disabilities.* *Neuropediatrics.,* 2015. **46.**
59. Annaz, D., et al., *Characterisation of sleep problems in children with Williams syndrome.* *Research in developmental disabilities,* 2011. **32.**
60. Ashworth, M., O. Palikara, and J. Herwegen, *Comparing parental stress of children with neurodevelopmental disorders: the case of Williams SYNDROME, Down syndrome and autism spectrum disorders.* *Journal of applied research in intellectual disabilities : JARID,* 2019. **32.**
61. Axelsson, E.L., et al., *Sleep problems and language development in toddlers with Williams syndrome.* *Research in developmental disabilities,* 2013. **34.**
62. Bailey, D.B., et al., *Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey.* *Journal of developmental and behavioral pediatrics : JDBP,* 2012. **33.**
63. Bailey, D.B., et al., *Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey.* *American journal of medical genetics Part A,* 2008. **146a.**
64. Baker, E.K. and A.L. Richdale, *Sleep patterns in adults with a diagnosis of high-functioning autism spectrum disorder.* *Sleep.,* 2015. **38.**

65. Bienvenu, T., A. Carrié, and N. Roux, *MECP2 mutations account for most cases of typical forms of Rett syndrome*. Human molecular genetics., 2000. **9**.
66. Borges, J.G., et al., *Executive functioning in obstructive sleep apnea syndrome patients without comorbidities: focus on the fractionation of executive functions*. Journal of clinical and experimental neuropsychology, 2013. **35**.
67. Bourgeron, T., *The possible interplay of synaptic and clock genes in autism spectrum disorders*. Cold Spring Harbor symposia on quantitative biology., 2007. **72**.
68. Braam, W., et al., *Melatonin for chronic insomnia in Angelman syndrome: a randomized placebo-controlled trial*. Journal of child neurology., 2008. **23**.
69. Breslin, J., et al., *Obstructive sleep apnea syndrome and cognition in Down syndrome*. Developmental medicine and child neurology, 2014. **56**.
70. Bruni, O., R. Ferri, and E. Vittori, *Sleep architecture and NREM alterations in children and adolescents with Asperger syndrome*. Sleep., 2007. **30**.
71. Bull, M.J., *Health supervision for children with Down syndrome*. Pediatrics, 2011. **128**.
72. Butler, M.G., *Prader-Willi syndrome: obesity due to genomic imprinting*. Current genomics., 2011. **12**.
73. Butler, M.G., J.L. Miller, and J.L. Forster, *Prader-Willi syndrome - clinical genetics, diagnosis and treatment approaches: an update*. Current pediatric reviews., 2019. **15**.
74. Caloway, C.L., G.R. Diercks, and D. Keamy, *Update on hypoglossal nerve stimulation in children with down syndrome and obstructive sleep apnea*. The Laryngoscope, 2020. **130**.
75. Carotenuto, M., M. Roccella, and F. Pisani, *Polysomnographic findings in fragile X syndrome children with EEG abnormalities*. Behavioural neurology, 2019. **2019**.
76. Carpizo, R., et al., *Smith-Magenis syndrome: a case report of improved sleep after treatment with beta1-adrenergic antagonists and melatonin*. The Journal of pediatrics., 2006. **149**.